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 Abstract 
 Objective: To evaluate the effectiveness of human recombi-
nant activated factor VII (rhFVIIa, NovoSeven) in avoiding 
hysterectomy postpartum in the management of severe post-
partum hemorrhage (PPH). 
 Methods: We performed a prospective cohort study at our 
university tertiary care center. Patients with severe post par-
tum hemorrhage (blood loss  > 2000 mL) and failed medical 
and uterus-preserving surgical management, were treated 
with intravenous bolus administration of rhVIIa. Main out-
come measures were cessation of bleeding, postpartum hys-
terectomy and thromboembolic events. 
 Results: In 20/22 patients included, PPH was caused primar-
ily by uterine atony, including 7 (32 % ) with additional lower 
genital tract lesion; in two women, it was due to pathologic 
placentation (placenta increta, 9 % ). One case of amniotic 
fl uid embolism and one woman with uterine inversion were 
included. Recombinant hFVIIa was successful in stopping 
the PPH and in preventing a hysterectomy in 20/22 women 
(91 % ). The remaining two patients with persistent bleeding 
despite rhFVIIa treatment, who underwent postpartum hys-
terectomy, had placenta increta. No thromboembolic event 
was noticed. 
 Conclusions: This study describes the largest single center 
series of rhFVIIa treatment for fertility preservation in severe 
postpartum hemorrhage published to date. Our data suggest 
that administration of rhFVIIa is effective in avoiding post-
partum hysterectomy after conservative medical and surgical 
measures have failed. Although randomized studies are lack-
ing, rhFVIIa should be considered as a second-line therapeu-
tic option of life-threatening postpartal bleeding, in particular 
if preservation of fertility is warranted and hysterectomy is to 
be avoided. 
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 Introduction 
 Major hemorrhage in the early postpartum period [postpar-
tum hemorrhage (PPH)] represents one of the most common 
causes for maternal mortality and morbidity worldwide  [18] . 
Life-threatening postpartal bleeding remains a challenging 
operative and/or medical treatment and may be caused by an 
incomplete expulsion of the placenta, by morbid placental 
adhesion, such as increte or percrete placentation, by uterine 
atonia, lower genital tract lacerations, uterine rupture or uter-
ine inversion or by primary or secondary coagulopathy  [6] . 
 Medical treatment usually includes uterotonic agents, such 
as intravenous oxytocin, methylergometrine, misoprostol or 
prostaglandin E2 (sulprostone)  [28] . Surgical interventions 
include the removal of the placenta or its remaining pieces, 
transvaginal surgical revision of genital lacerations, uterine 
tamponade (e.g., by balloon catheter), uterine packing, lapa-
rotomy, uterine compression sutures, such as brace sutures 
(e.g., Hayman technique  [10] , B-Lynch sutures or square 
sutures), stepwise uterine devascularization or hypogastric 
artery ligation  [13] . Embolization of both uterine arteries is 
another option to treat severe postpartum hemorrhage; how-
ever, logistic prerequisites with 24-h availability of emer-
gency interventional radiology are necessary. If conservative 
medical and surgical measures fail, emergency hysterectomy 
is often the last possibility to stop bleeding. However, hyster-
ectomy should be avoided whenever possible to preserve fer-
tility, particularly in young women. Furthermore, postpartum 
hysterectomy is affected by a signifi cant maternal morbidity, 
even when performed by experienced surgeons  [15] . The inci-
dence of PPH not responding to classic obstetric maneuvers 
and uterotonic drugs is reported to be 1.0–1.8 in 1000 deliver-
ies  [6] . After failure of uterotonic drugs, transfusion therapies 
and surgical measures, the management of severe hemorrhage 
may also include the use of recombinant human factor VIIa 
(rhFVIIa, NovoSeven  ®  , Novo Nordisk, Bagsvaerd, Denmark), 
a tissue factor-activated prohemostatic agent originally intro-
duced and licensed for the treatment of patients with congeni-
tal or acquired hemophilia and antibodies against factor VIII 
or IX  [17] . The hemostatic effect of recombinant factor VIIa, 
which is administered in a supraphysiologic pharmacological 
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dosage, is limited to the site of injury, because it needs tissue 
factor to become effective in the promotion of coagulation. 
RhFVIIa enhances the rate of thrombin generation by directly 
activating factors IX and X on platelets and thus enhancing the 
rate of thrombin generation  [12] . Despite the lack of appropri-
ately randomized controlled clinical trials, evidence from the 
literature indicates that rhFVIIa has a promising effi cacy in 
severe non-surgical bleeding or trauma and other conditions 
with a 0.4 % – 2 % incidence of thrombotic complications based 
on published data  [14, 17] . In postpartum hemorrhage, the use 
of this conservative treatment option has been described pre-
viously. However, to date, only case reports and small case 
series describing the rhFVIIa use in postpartum hemorrhage 
have been reported; in most cases, it was used only after post-
partum hysterectomy  [1, 4, 7, 24, 26] . The results of two reg-
istries (Northern European  [3] and Australian New Zealand 
 [25] ) had included larger series; however, these are collected 
data from many different centers with different inclusion 
criteria and different management strategies of postpartum 
hemorrhage. No study so far has specifi cally addressed the 
question of whether fertility can be preserved by the use of 
rhFVIIa through avoiding postpartum hysterectomy; thus, 
all previous studies included patients who were treated with 
rhFVIIa only at the time or after postpartum hysterectomy has 
been performed  [5] . The aim of the present study was, there-
fore, to determine the clinical value of rhFVIIa administration 
in the treatment of postpartum hemorrhage prior to hyster-
ectomy with the goal to preserve fertility in a larger single 
center series of patients. 
 Materials and methods 
 Our prospective cohort analysis included all 22 consecutive patients 
from April 2004 to May 2008 with severe postpartum hemorrhage, who 
had been treated with rhFVIIa as a rescue therapy after unsuccessful 
medical and surgical uterine-preserving management at the University 
Hospital Bern, Switzerland. Due to the study design, this study was 
exempted from the institutional review board approval. In all patients, 
uterine preservation and avoidance of hysterectomy was the goal of 
rhFVIIa therapy. Included patients showed no history or evidence of 
known factor VIII or IX defi ciency prior to the treatment. RhFVIIa was 
injected intravenously with a single mean dosage of 71  µ g/kg body-
weight (range 34 – 137  µ g/kg). Repeated administration within 60 min, 
due to insuffi cient effi cacy, was necessary in two patients. 
 The clinical algorithm in postpartum hemorrhage prior to rhFVIIa 
treatment included uterotonic drugs, such as i.v. oxytocin, i.v. methy-
lergometrine, misoprostol (1000  µ g rectally as a single dose), i.v. 
sulprostone, fl uid management, the substitution of erythrocyte con-
centrates, fresh frozen plasma (and/or fi brinogen administration) and 
platelet transfusion if required. Surgical interventions included the 
identifi cation and repair of lower genital tract lesions, the manual 
and instrumental uterine revision and curettage, uterine tamponade 
by a balloon catheter or by surgical towels, laparotomy and uterine 
compression sutures (B-Lynch or Pereira sutures, Hayman suture 
technique, square sutures), uterine artery embolization in 1 case, and 
fi nally, if unresponsive to conservative treatments and rhFVIIa appli-
cation, hysterectomy was performed. Recombinant hFVII treatment 
was initiated if bleeding was not controllable by medical or surgical 
procedures, as a last step before proceeding with a hysterectomy. 
 Hematologic parameters were monitored repetitively before, dur-
ing and after postpartum hemorrhage treatment, and rhFVIIa therapy 
was initiated after given indication was confi rmed by a hemostasio-
logist. Follow-up monitoring was individualized and included at least 
the following: postoperative intensive care unit surveillance, hema-
tologic screening of hemoglobin, hematocrit, thrombin time, inter-
national normalized ratio, fi brinogen, screening of liver and kidney 
functions, and clinical evaluation. The hemostatic effi cacy of the drug 
was evaluated clinically and considered good when visible bleeding 
cessation was noticed within 30 min following rhFVIIa administra-
tion. Posttherapeutic transfusion rates of blood products were indirect 
parameters for continuing bleeding and therefore for treatment fail-
ures. In order to prevent posttherapeutic clotting, a prophylactic low 
dose of heparin was administered during hospitalization, after throm-
bocyte levels reached more than 100 G/l. Patients were followed until 
6 weeks postpartum to exclude thromboembolic events. 
 Data were anonymized for analysis. Statistical calculations 
including paired  t -test and rank sum, where applicable, were per-
formed with commercially available software (GraphPadPrism4, 
GraphPad Software Inc., La Jolla, CA, USA) and reached signifi -
cance with P < 0.05. 
 Results 
 During the study period, 22 patients with a mean age of 
31.8 years (21 – 43 years) and a mean bodyweight at hospi-
talization of 66.90 (50 – 95) with a massive postpartum hem-
orrhage (defi ned as estimated blood loss  > 1500 mL, range 
2000 – 15,000 mL) were treated with rhFVIIa after failure of 
conservative and/or surgical therapy. The mean gestational 
age was 38.4 weeks post menstruation (range 30 – 42 weeks 
p.m.). Patients ’ characteristics and delivery modes are shown 
in Table  1 . 
 Uterine atony was present in 20 cases (91 % ), pathologic 
placentation (placenta increta) in two women (9 % ), placenta 
accreta in two cases (9 % ) whereas placenta retention was found 
in four patients (18 % ) and lower genital tract lesions in seven 
cases (32 % ). One uterine inversion (case E) was diagnosed in 
our patient series. 
 Conservative surgical treatment comprised curettage in 
73 % (16/22) and uterine tamponade with surgical towels or 
by balloon catheters in 50 % (11 women). Uterine packing 
sutures were applied in 54 % (12 cases) and operative revi-
sion and suturing of the lower genital tract was performed in 
32 % (7 women). In a case of surgical bleeding, the left uterine 
artery was embolized. 
 Recombinant hFVIIa was successful in stopping the 
postpartum hemorrhage and preserving the uterus in 20/22 
patients (91 % ). 
 One woman (case L, Table  2 ) showed an initially reduced 
bleeding pattern, but continuing blood loss after medical, con-
servative operative therapy and rhFVIIa treatment, therefore 
requiring postpartum hysterectomy. After uterine resection, 
bleeding was stabilized. 
 In one intraoperative application after massive packed red 
blood cell transfusions, rhFVIIa was unsuccessful in stopping 
a surgical bleeding, therefore postpartum hysterectomy was 
initiated (case P). In both cases of failure of rhFVIIa treat-
ment, an increte placenta was present. 
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 One woman was rehospitalized 18 days after success-
ful rhFVIIa treatment of a uterine atony. Massive bleeding 
occurred again due to an incomplete placenta evacuation and 
was managed by conservative operative therapies (curettage 
and tamponade, case A) a hematologic follow-up 6 months 
after the last event showed a mild thrombocyte aggregation 
disorder without other proofs of hemophilia. 
 Disseminated intravascular clotting (DIC) as an acquired 
hemorrhagic diathesis characterized by systemic activation of 
coagulation was confi rmed by a hematologist in each case, 
and was present to some degree in 18 patients at the time of 
treatment. 
 No clinical thromboembolic event occurred in our case 
series. Patients ’ history showed two women (cases S and H) 
with a history of central pulmonary thromboembolism, with 
consecutive anticoagulant medication during pregnancy. Both 
showed no clinical evidence for a relapse or thromboembolic 
complications under rhVIIa therapy. A thromboembolic event 
was excluded by radiologic examination in a patient after 
an intraoperative epileptic seizure (case M). Other adverse 
events comprised a transient pulmonary edema in one woman 
(case C), one secondary renal insuffi ciency (case F) and one 
successfully conservatively treated paralytic ileus (case V); 
however, it seems unlikely that there is any relation between 
these adverse events and rhFVIIa treatment. 
 The mean hemoglobin prior to rhFVIIa treatment was 
70.3 g/L (40 – 18 g/L) with a mean hematocrit of 0.21 
(0.12 – 0.35) and transfusion mean of 9.7 units of erythrocyte 
concentrates (2 – 18 units). After rhFVIIa injection, signifi -
cantly less red blood cell transfusions (2.6 units, P < 0.001), 
fresh frozen plasma substitutions (1.8 units, P < 0.001; vs. 
6.8 units pre-therapeutically) and thrombocyte transfusions 
(1.2 units vs. 0.2 units, P < 0.001) were necessary (Table  2 ). 
Transfusions and rhFVIIa therapy resulted in a signifi -
cant rise in mean hemoglobin to 90.8 g/L (66 – 120 g/L, 
P < 0.001) and in mean post-therapeutic hematocrit of 0.26 
(0.19 – 0.35, P < 0.002). Partial normalization of coagulative 
values was examined approximately 24 h after rhFVIIa 
treatment with signifi cant changes in mean values of fi brin-
ogen (1.8 g/L vs 4.1 g/L, P < 0.001), partial thrombin time 
(80.5 % vs. 100 % , P < 0.001) and international normalized 
ratio (1.21 vs. 1.00, P < 0.01) when compared to serologic 
screening a maximum 12 h before rhFVIIa therapy (Table  3 
and  4 , respectively). 











Type of delivery Obstetric diagnosis
Case A 27 70 39 1 1 Secondary cesarean section Uterine atony, monochorionic 
diamniotic twin pregnancy
Case B 36 62 40 2 1 Vacuum extraction Paravaginal tear, cervical laceration, 
uterine atony
Case C 34 66 42 2 2 Spontaneous after induction Uterine atony
Case D 28 59 41 2 2 Spontaneous after induction Uterine atony, cervical laceration, 
placenta retention
Case E 34 62 39 1 1 Vacuum extraction Placenta retention, inversion of the 
uterus, cervical laceration, uterine 
atony
Case F 41 72 41 1 1 Secondary emergency cesarean 
section
Uterine atony
Case G 33 64 42 2 2 Secondary cesarean resection Uterine atony, tear in mesosalpinx
Case H 37 60 30 2 2 Secondary cesarean section Chronic placental insuffi ciency, 
uterine atony
Case I 27 72 40 1 1 Vacuum extraction Uterine atony, cervical and vaginal 
laceration
Case J 43 54 31 1 1 Primary cesarean section HELLP, placenta accreta, uterine atony
Case K 31 63 42 1 1 Vacuum extraction Uterine atony, cervical laceration
Case L 32 70 37 2 2 Primary cesarean section Increte placenta previa
Case M 30 74 38 1 1 Secondary cesarean section Uterine atony, tear, HELLP 
postpartum
Case N 21 75 39 1 1 Primary cesarean section Uterine atony
Case O 31 70 41 1 1 Secondary emergency cesarean 
section
Uterine atony, uterine artery lesion
Case P 28 51 36 2 2 Spontaneous Placenta increta
Case Q 33 50 41 3 2 Spontaneous Uterine atony, cervical laceration
Case R 26 80 41 3 2 Vacuum extraction Uterine atony
Case S 31 95 32 1 0 Primary cesarean section Uterine atony, HELLP
Case T 32 70 40 3 3 Primary resection Uterine atony
Case U 36 60 31 2 2 Secondary cesarean section Uterine atony, placenta accreta
Case V 29 72.5 41 3 1 Secondary cesarean section Cervical laceration, uterine atony
HELLP = hemolysis, elevated liver enzymes, low platelet count.
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 Table 2  Surgical treatment and outcome after rhFVIIa application. 
Transfusions 
RBC/FFP/PLT












Initially good response, second 
uterine atony, placenta 
retention after 18 days
Case B 5/1/1 1/-/- 2x operative revision of the lower 
genital tract, tamponade
 2000 2500 Initially good response, second 
dosage necessary
Case C 4/8/2 -/-/- Curettage, tamponade  2400 2500 Good response
Case D 4/4/- -/-/- Curettage, tamponade, operative 
revision of the cervix reversion, 
B-Lynch sutures, square sutures 
of the uterus,
 2000 2000 Good response
Case E 18/10/2 -/-/- Revision of cervix, curettage, 
tamponade
n.a. n.a. Good response
good response, secondary renal 
insuffi ciency,
Case F 17/17/3 -/-/- Curettage, tamponade, operative 
revision, uterine pack sutures
3000 3000 Bladder laceration, wound 
infection
Case G 8/8/2 1/-/- Curettage, revision, sutures 2800 3000 Good response
Case H 8/4/- -/-/- Cesarean, revision  2800 2800 Good response
Case I 17/8/1 -/-/- Curettage, cervix-suture 2700 2700 Good response
Case J 5/3/2 1/3/- Cesarean, revision, B-lynch 
sutures, curettage
4500 4500 Good response
Case K 10/10/2 -/-/- Curettage, tamponade, cervix-
revision
3000 3000 Good response
Case L 9/6/2 3/1/- Cesarean,revision, sutures, 
curettage, hysterectomy p.p.
4500 6500 No response, bleeding 
continued
Case M 12/8/- -/-/- Cesarean, revision, B-lynch 
sutures
4250 4500 Good response
Case N 12/7/1 -/-/- Curettage, tamponade, revision, 
B-lynch sutures
5100 5100 Good response
Case O 15/12/4 -/-/2 Revision, tamponade, B-Lynch 
sutures, embolization left 
uterine artery
6700 7500 Good response, surgical bleed-
ing reduced
Case P 7/8/1 0/4/1 
23/18/1
2x curettage, hysterectomy n.a. 15000 Go response, bleeding 
continued
Case Q 8/6/- -/2/- Curettage, revision of the cervix 3000 3000 Good response
Case R 2/-/- -/-/- Curettage, tamponade 2000 2000 Good response
Case S 5/2/- 1/3/1 B-lynch, pereira sutures, 
intrauterine catheter
4000 5000 Good response
Case T 5/5/1 1/-/- curettage, 2x intrauterine 
catheter, tamponade
2500 3500 Good response
Case U 2/4/- 3/-/- B-Lynch, Pereira and uterine 
square sutures
2800 3000 Good response
Case V 8/8/1 4/4/- B-Lynch, Hayman sutures, 
curettage
5500 6000 Good response
 RBC = packed red blood cell transfusion, FFP = fresh frozen plasma, PLT = platelet transfusion, n.a. = not available. 
 Hematologic follow-up after 6 months was performed in 
fi ve cases and revealed one factor XIII defi ciency and one 
protein S defi ciency (cases B and R). A mild thrombocyte 
aggregation disorder was diagnosed in one woman (case A). 
 Comment 
 Massive PPH remains one of the most common causes of 
maternal mortality therefore demanding precise management 
protocols. After failure of medical and conservative surgical 
measures  [11] , emergency postpartum hysterectomy is often 
unavoidable. The loss of fertility especially in women deliver-
ing the fi rst child including an augmented mortality of preterm 
neonates often associated with pathologic placentation has a 
major psychologic impact. Depressive disorders are known 
to impair the quality of life of women who had to undergo 
emergency postpartum hysterectomy  [16] . Furthermore, post-
partum hysterectomy is associated with a high blood loss, a 
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Case A   77 23   64 1.56 81.6   74 1.12 11.5
Case B   59 17 104 1.59 68.2   98 1.19 12
Case C   64 19 133 1.91 40.1   99 1   9.8
Case D   71 20   68 0.52 57.6   44 1.64 35.1
Case E   68 20   68  0.89 75.1   39 1.76 14.4
Case F   77 24   79 0.97 50.9   32 1.97 17.7
Case G   71 21 110 n.a. n.a.   79 1.16 n.a
Case H   52 16 136 2.14 41 100 1.06 23.6
Case I   63 18   86 n.a. n.a.   91 1.08 n.a
Case J   65 19   68 1.43 41   85 1.13 15.6
Case K 118 35   85 1.82 40.5   88 1.16 12.7
Case L   48 13   49 1.32 41.5   88 1.15 13.6
Case M   72 21 218 3.96 33.8 100 1 10.2
Case N   66 22 137 1.31 49.2 100 1 13.9
Case O   40 12   33 1.24 55.2   57 1.34 13.8
Case P   66 20   97 n.a. n.a. 100 1 n.a
Case Q   86 25 126 1.63 50.4   65 1.24 12
Case R   83 25 234  3.25 29 100 1 11.7
Case S   82 23   46 1.33 38.8   72 1.2 22.8
Case T   72 22 158 n.a. n.a.   78 1.16 n.a
Case U   71 21 193 38.1 38.1   96 1.02 11.4
Case V   70 21   60 n.a. n.a.   88 1.15 n.a
 n.a.=not available. 
need for blood transfusion, high intraoperative morbidity and 
postoperative complications. 
 Application of rhFVIIa in patients with pre-existent normal 
coagulation system, who experience excessive bleeding, has 
been explored in trauma and is increasingly used in obstetric 
and gynecologic indications  [3, 19] . Previous reports describ-
ing the effect of administration of rhFVIIa in PPH are of 
limited numbers and predominantly associated with use after 
postpartum hysterectomy. 
 The results of our study  – to our knowledge, the largest pub-
lished so far  – a single center cohort for fertility preservation 
by rhFVIIa, clearly suggest that rhFVIIa is effective as a sec-
ond line treatment in controlling bleeding in severe PPH, and 
specially, in avoiding the need for emergency hysterectomy in 
most cases if used early enough. With an overall success rate 
of 90.1 % (n = 20/22), rhFVIIa was effective in achieving suf-
fi cient hemostasis, comparable to published reports  [17] . 
 Present metabolic acidosis in one patient with continuing 
bleeding (case L) might have impaired the hemostatic effect 
of rhFVIIa  [18] (data not shown). Both failures of therapy 
(cases L and P) showed pathological placentation with inva-
sion into the myometria, suggesting a possible limitation of 
rhFVIIa in analogy to surgical bleeding (as in case O where 
additional embolization of the left uterine artery was neces-
sary) although in contrast to recently published case reports 
especially in combination with arterial embolization  [2, 20] . 
Since the pharmacological mechanism of rhFVIIa is mediated 
via a thrombin burst and is platelet dependent, a suffi cient 
number of platelets (e.g.,  > 50 G/l) seems to be one prereq-
uisite, as postulated previously  [21] . The low platelet count 
might be an additional explanation of the missing response in 
case L, and eventually also in case O where additional embo-
lization was necessary after rhFVIIa treatment. 
 The optimal dose of rhFVIIa is yet unknown. Our data sug-
gest that a single dose of 70  µ g/kg may be suffi cient in most 
cases to control severe PPH in agreement with previous litera-
ture reviews  [24] . According to consensus recommendations 
for the off-label use of recombinant factor VIIa therapy  [27] a 
mean dosage of 71  µ g/kg was capable to arrest bleeding with 
the lowest dosage of 36  µ g/kg bodyweight. 
 One important drawback of this study is that it is not a 
randomized controlled trial; we therefore cannot exclude 
confounding effects of the concomitant surgical or medical 
treatment. However, due to known diffi culties in perform-
ing randomized trials in postpartum hemorrhage, there are 
no such data available in the literature  [9] . Nevertheless, the 
astonishing clinical hemostatic effect of rhFVIIa was evident 
in almost all cases in our series. Furthermore, in our cases, 
rhFVIIa treatment was given as the  “ last resort ” before pro-
ceeding with hysterectomy as also proposed by a recently 
published Australian clinical guideline  [29] . The treatment 
success of 91 % to avoid hysterectomy is therefore evident 
even in the absence of an appropriately randomized control 
group. Thus, the optimal timing of its usage should be prior 
to hysterectomy. In agreement with other clinical trials, our 
data suggest that secondary effects, such as thromboembo-
lic complications, are probably rare ( < 1.4 % )  [10, 27] even 
in high-risk patients. Severe PPH associated with previous 
thromboembolic events did not alter the safety profi le in 
emergency use of rhFVIIa in our case series. However, due 
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to co-treatment and due to the limited case series numbers, 
adverse events may be underestimated. Since most reported 
thrombembolic events in the arterial and venous system fol-
lowed the use of rhFVIIa for unlabeled indications, random-
ized controlled trials in PPH are needed to establish the safety 
and effi cacy of rhFVIIa in patients without hemophilia  [23] . 
 The economic impact of rhFVIIa therapy is diffi cult to quan-
tify. In our study, we did not evaluate cost-benefi t analysis. 
According to preceding publications, rhFVIIa is cost effective 
in blunt trauma  [27] and intracerebral hemorrhage, when avoid-
ing 10 or more units of packed red blood cells, not calculating 
the benefi ts of prevention of multiorgan failure and live salvage 
 [8] . However, these data do not take the costs of surgical revi-
sions into account. Furthermore, as in the case of PPH, the costs 
of postpartum hysterectomy itself and the patient ’ s benefi ts if 
hysterectomy is avoided and therefore fertility is preserved, are 
other important issues in the cost-benefi t calculation. 
 The commercially available preparation of rhFVIIa 
(NovoSeven  ®  ) is licensed for use in hemophilic patients 
affected by inhibiting antibodies towards Factor VIII or XI. 
The use in postpartum hemorrhage is therefore off-label; this 
fact has to been taken into account if rhFVIIa is used for this 
indication. 
 Since rhFVIIa was able to stop PPH and preserve fertility 
in 91 % of all treated patients, our study suggests that admin-
istration of rhFVIIa should be considered as a second-line 
therapeutic option of life-threatening postpartum hemorrhage 
in conjunction with other medical and uterine-preserving 
surgical interventions, in particular if preservation of fertility 
is warranted. 
 Condensation 
 Recombinant human factor VIIa is an effective second-line thera-
peutic option for life-threatening postpartal hemorrhage to avoid 
postpartum hysterectomy and preserve fertility after conservative 
medical and surgical measures have failed. 
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